0.6555

13.20% -0.0945

AEON Biopharma Inc. (AEON)

Overview News Price History Discussions Forecast

AEON Biopharma Inc. stock is traded at $0.6555, with a volume of 1.27M. It is down -13.20% in the last 24 hours and down -93.04% over the past month. AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.

Previous Close:

$0.75

Open:

$0.686

24h Volume:

1.27M

Relative Volume:

2.84

Market Cap:

$721.96K

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-86.60%

1M Performance:

-93.04%

6M Performance:

-98.93%

1Y Performance:

-99.93%

1-Day Range:

$0.61

$0.73

1-Week Range:

$0.61

$2.04

52-Week Range:

$0.61

$1,236.24

AEON Biopharma Inc. Stock (AEON) Company Profile

Name

AEON Biopharma Inc.

Sector

Healthcare (1188)

Industry

Biotechnology (679)

Phone

(949) 354-6499

Address

5 Park Plaza, Suite 1750, Irvine

Employee

Twitter

Next Earnings Date

Latest SEC Filings

AEON's Discussions on Twitter

Compare AEON with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AEON AEON Biopharma Inc.	0.6555	721.96K	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	490.11	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	688.45	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	632.13	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.19	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	112.67	27.34B	3.30B	-501.07M	1.03B	-2.1146

AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-18-23	Initiated	H.C. Wainwright	Buy

AEON Biopharma Inc. Stock (AEON) Latest News

Mar 02, 2025

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable

Mar 02, 2025

Feb 27, 2025

AEON Biopharma, Inc. Deloitte, Inc. Announces Update of Phase 2 Double Blind Study of ABP-450 in the Treatment of Migraine - Marketscreener.com

Feb 27, 2025

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine - Marketscreener.com

Feb 27, 2025

AEON Biopharma, Inc. Announces Executive Changes -May 16, 2024 at 04:28 pm EDT - Marketscreener.com

Feb 27, 2025

AEON Biopharma, Inc. Announces Strategic Reprioritization to Pursue A Biosimilar Pathway for ABP-450 - Marketscreener.com

Feb 27, 2025

AEON Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com

Feb 27, 2025

Feb 26, 2025

Stock market news: AEON Biopharma plummented by 65.33% while Enveric Biosciences skyrocketed by 90.68% during midday trading - Business Upturn

Feb 26, 2025

Stock market today: AEON Biopharma plunged by 63.17% while Enveric Biosciences surged by 124.66% in early trading - Business Upturn

Feb 26, 2025

Feb 25, 2025

AEON Biopharma To Implement 1-for-72 Reverse Stock Split For Compliance With NYSE Rules - Nasdaq

Feb 25, 2025

Feb 24, 2025

AEON Biopharma executes reverse stock split to comply with NYSE standards - Investing.com Australia

Feb 24, 2025

Aeon Biopharma Approves 1-For-72 Reverse Stock Split -February 24, 2025 at 02:53 pm EST - Marketscreener.com

Feb 24, 2025

AEON Biopharma Announces 1-for-72 Reverse Stock Split Effective February 26, 2025 - Nasdaq

Feb 24, 2025

Can AEON's 1-for-72 Reverse Split Save Its NYSE Listing Status? - StockTitan

Feb 24, 2025

Feb 10, 2025